ExodusPoint Capital Management’s LENZ Therapeutics LENZ Stock Holding History

ExodusPoint Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$527K	Buy	57,577 +34,430	+149%	+$484K	﹤0.01%	1179
2025 Q4	$370K	Buy	+23,147	New	+$675K	﹤0.01%	1254
2025 Q2	–	Sell	-27,829	Closed	-$715K	–	2053
2025 Q1	$715K	Buy	+27,829	New	+$685K	0.01%	1014
2022 Q4	–	Sell	-1,834	Closed	-$41K	–	2222
2022 Q3	$41K	Buy	+1,834	New	+$43.7K	﹤0.01%	1798

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

ExodusPoint Capital Management's LENZ Position: Q1 2026 in Review

ExodusPoint Capital Management increased its LENZ Therapeutics (LENZ) stake by 149% in Q1 2026, buying an estimated $484K and bringing the position to 57,577 shares worth $527K. The position accounts for ﹤0.01% of the portfolio, ranked #1179.

ExodusPoint Capital Management first reported a position in LENZ in Q3 2022 and has held it in 4 quarters since. The position peaked at $715K in Q1 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

ExodusPoint Capital Management held 57,577 shares of LENZ Therapeutics worth $527K as of Q1 2026.
ExodusPoint Capital Management bought 34,430 LENZ Therapeutics shares in Q1 2026, an estimated $484K.
LENZ Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1179 holding.
ExodusPoint Capital Management first reported a position in LENZ Therapeutics in Q3 2022 and has held it in 4 quarters since.
ExodusPoint Capital Management's LENZ Therapeutics position peaked at $715K in Q1 2025.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.